Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur seeks FDA approval for combination vaccine
Pentacel vaccine is the first DTaP-based combination vaccine candidate for use in infants in the US that includes both polio and Hib vaccine components. The vaccine is already
Pentacel vaccine is the first DTaP-based combination vaccine candidate for use in infants in the US that includes both polio and Hib vaccine components. The vaccine is already
This study will enroll 300 patients with moderate to severe acne at 20 investigational centers throughout the US. The study design will evaluate three dosage strengths of incyclinide
The benefits of fast track status include scheduled meetings seeking FDA input into development plans, the option of submitting a new drug application in sections rather than submitting
The combined company will have four products in its pipeline. AlgoRx’s portfolio of pain management drug candidates includes ALGRX 3268, which is in phase III clinical trials, ALGRX
Cubicin was originally approved in September, 2003, at 4 mg/kg intravenously once daily for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive organisms,
The 12-patient trial is the world’s first study to use a viral vector for the treatment of an adult neurological disease. The vector was injected into a specific
In the study, performed by Dr Yvonne Paterson, scientific founder of Advaxis, Listeria vaccine treatment was found to be significantly more effective than comparable DNA vaccines, even though
The $9 million follow-on investment is on top of the original founders’ commitment of approximately $14 million, which also included Hadasit, Star Ventures, and the Jerusalem Development Authority,
The company also expects to commence dosing patients with mild to moderate Alzheimer’s disease in a Phase 2a clinical trial in the next several weeks. “This study has
These partnerships will leverage Quidel’s global capabilities to collaborate with osteoporosis research institutions for the development of new markers which may benefit osteoporosis and post-menopausal patients. “With these